Low-Molecular-Weight Heparin in Atherosclerotic Stroke

Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?

Clinical Sciences Genome-Wide Association Study of Vascular Dementia Elisabeth M.C. Schrijvers, MD; Britta Schürmann, PhD; Peter J. Koudstaal, MD, PhD; Hendrik van den Bussche, MD; Cornelia M. Van Duijn, MD, PhD; Frank Hentschel, MD; Reinhard Heun, MD; Albert Hofman, MD, PhD; Frank Jessen, MD; Heike Kölsch, PhD; Johannes Kornhuber, MD; Oliver Peters, MD; Fernando Rivadeneira, PhD; Eckart Rüther...

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Low molecular weight heparin.

Heparin and low-molecular-weight heparin.

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have repl...

Perioperative Low - Molecular - Weight Heparin

In previous randomised clinical trials of thromboprophylaxis after total hip replacement, low-molecular-weight heparin has been given for an arbitrary 7 to 14 days. The risk factors are mainly perioperative and it is possible that a shorter course may be adequate. We assessed the safety and effectiveness of a three-day course. We assessed 156 primary THR patients after randomisation to either a...